FeesSafety
Pluang+

Zepp Health to report Q3 2026 earnings on Nov 22 with a live call at 8:30 p.m. ET

Company Fundamentals
10 Nov 2026, 13:30 WIB
PRNewsWire
View Source
Neutral
Zepp Health to report Q3 2026 earnings on Nov 22 with a live call at 8:30 p.m. ET

Zepp Health Corporation will announce its unaudited financial results for the third quarter of 2026 on November 22. The company will host a conference call at 8:30 p.m. Eastern Time the same day, providing investors and analysts an opportunity to hear management's insights. Zepp Health is a global leader in smart wearables and health technology, known for its Amazfit brand and integrated tech platform. The earnings report will offer updates on the company's performance and outlook amid its ongoing global growth efforts.

Zepp Health Corporation's upcoming Q3 2026 financial results provide context for technology sector performance. For readers following Technology-sector US stocks on Pluang, 51 of 150 stocks rose while 89 fell. Notable movers include ZETA at USD 31.54 with a 1-day change of -2.71%, PUBM at USD 18.56 down 2.47%, and AXTI at USD 41.93 down 2.28%. These figures are as of Nov 10, 2026 18:12 WIB.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
59 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
59 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
59 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
59 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App